SCHEDULE: Janus Henderson Boosts Avadel Pharma Stake to 11.5%

Janus Henderson Group plc has increased its beneficial ownership in Avadel Pharmaceuticals PLC to 11.5% of common stock, holding 11,132,131 shares as of June 30, 2025.

Summary

• Janus Henderson Group plc reported beneficial ownership of 11,132,131 shares of Avadel Pharmaceuticals PLC common stock.
• This represents 11.5% of Avadel Pharmaceuticals PLC's common stock.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to a previously reported ownership position.
• Janus Henderson Group plc, a Jersey-based entity, is classified as an investment adviser and a parent holding company.
• The reported shares are held with shared voting power and shared dispositive power.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G/A) by an institutional investor, Janus Henderson Group plc, reporting its stake in Avadel Pharmaceuticals PLC. It does not contain operational or financial performance data, nor does it express a sentiment regarding the issuer's prospects. The reported ownership percentage is a factual update.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional holder's updated stake provides transparency regarding the company's ownership structure.

Key Dates

Keywords

Avadel Pharmaceuticals, Janus Henderson, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Pharmaceutical